Join to View Full Profile
8932 SW 97th AveSte 100Miami, FL 33176
Phone+1 305-243-5302
Dr. Rose is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of South Florida Morsani College of Medicine/Moffitt Cancer Center/Tampa General HospitalFellowship, Hematology and Medical Oncology, 2020 - 2023- University of South Florida MorsaniFellowship, Hospice and Palliative Medicine, 2019 - 2020
- University of South Florida MorsaniResidency, Internal Medicine, 2016 - 2019
East Tennessee State University James H. Quillen College of MedicineClass of 2016
Certifications & Licensure
FL State Medical License 2018 - 2026
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Hospice and Palliative Medicine
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- Outcomes in patients with classic Hodgkin lymphoma refractory or intolerant to brentuximab vedotin and anti-PD-1 therapy: a real world analysis from 15 U.S. academic c...Timothy J Voorhees, Eric M McLaughlin, Pallawi Torka, Jorge Florindez, Na Hyun Kim
Blood Cancer Journal. 2025-03-26 - Autologous Hematopoietic Cell Transplantation Consolidation for First Response is Associated With Longer Survival Among Patients With Nodal Peripheral T Cell Lymphoma.Yumeng Zhang, Ashley Rose, Sushmita Khadka, Biwei Cao, Jennifer Eatrides
Transplantation and Cellular Therapy. 2024-09-01 - 3 citationsDelineation of clinical course, outcomes, and prognostic factors in patients with T-cell prolymphocytic leukemia.Ashley Rose, Ling Zhang, Akriti G Jain, Abida Poovathukaran Babu, Lubomir Sokol
American Journal of Hematology. 2023-06-01
Abstracts/Posters
- Elotuzumab in Combination with an Immunomodulatory Agent (IMID) in Patients with Multiple Myeloma Refractory to Imids and/or Daratumumab: A Single-Institution Analysis...Ashley Rose, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Impact of Rituximab in the Clinical Outcomes of Hairy Cell Leukemia: A Retrospective Single-Institution AnalysisAshley Rose, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Authored Content
- Connecting the Dots: A Case of Myeloid SarcomaMay 2018
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
